Impact of Solifenacin Succinate for Treatment of Acute Irritative Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer
Phase of Trial: Phase III
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Solifenacin (Primary)
- Indications Bladder disorders; Overactive bladder
- Focus Therapeutic Use
- Acronyms VesiCaP
- 17 May 2017 Status changed from recruiting to discontinued.
- 01 Dec 2016 Status changed from completed to recruiting.
- 07 Mar 2016 New trial record